www.cariboubio.com Open in urlscan Pro
69.63.141.106  Public Scan

Form analysis
0 forms found in the DOM

Text Content

We are a clinical-stage biopharmaceutical company focused on developing
transformative genome-edited allogeneic cell therapies for devastating human
diseases.


PRECISION GENOME EDITING

Our next-generation CRISPR genome-editing technology enables superior
specificity and precision. Our patented chRDNA (CRISPR hybrid RNA-DNA)
technology allows for complex genome editing, including multiplex gene knockout
and insertion, while maintaining genomic integrity.

Learn about chRDNA


OFF-THE-SHELF CELL THERAPIES

We are developing allogeneic, or off-the-shelf, CAR-T and CAR-NK cell therapies
from healthy donor cells to address the limitations of currently approved
therapies.

View our pipeline


ARMORED FOR ANTITUMOR ACTIVITY

We believe armoring is the key to unlocking the full potential of allogeneic
cell therapies. By applying our chRDNA technology and genome-editing strategies,
we are developing allogeneic cell therapies armored for potential improvement of
antitumor activity.

Armoring for activity

--------------------------------------------------------------------------------

> “Caribou is a leader in the CRISPR field, successfully leveraging its
> proprietary genome-editing technology to develop allogeneic cell therapies
> that are potentially transformative for patients.”
> 
> Jennifer Doudna, PhD
> Co-founder of Caribou
> Co-recipient of the 2020 Nobel Prize in Chemistry
> 
>  

--------------------------------------------------------------------------------


JOIN THE HERD

Caribou Biosciences is a pioneer in genome editing and cell therapy development,
and we are seeking talented and passionate individuals to join our team.

Working at Caribou

 

 * About
    * Leadership
    * Board of Directors
    * Scientific Advisory Board
    * Partnering

 * Technology
    * chRDNA technology
    * CAR-T cell therapy platform
    * CAR-NK cell therapy platform
    * Scientific publications

 * Pipeline
    * T cell pipeline
    * NK cell pipeline
    * Clinical trials

 * Careers
    * Job Opportunities
    * Values
    * DE&I
    * Benefits
       * Summary of Benefits

 * Investors
    * News & Events
       * News Releases
       * Events
       * Presentations
   
    * Presentations
    * Stock Information
       * Stock Quote & Chart
   
    * Corporate Governance
       * Documents & Charters
       * Leadership
       * Board of Directors
   
    * Financials & Filings
       * SEC Filings
       * Annual Report
   
    * IR Resources
       * FAQs
       * Email Alerts
       * Contact IR

 * Contact


 * Home
 * About
    * Leadership
    * Board of Directors
    * Scientific Advisory Board
    * Partnering

 * Technology
    * chRDNA technology
    * CAR-T cell therapy platform
    * CAR-NK cell therapy platform
    * Scientific publications

 * Pipeline
    * T cell pipeline
    * NK cell pipeline
    * Clinical trials

 * Careers
    * Job Opportunities
    * Values
    * DE&I
    * Benefits
       * Summary of Benefits

 * Investors
    * News & Events
       * News Releases
       * Events
       * Presentations
   
    * Presentations
    * Stock Information
       * Stock Quote & Chart
   
    * Corporate Governance
       * Documents & Charters
       * Leadership
       * Board of Directors
   
    * Financials & Filings
       * SEC Filings
       * Annual Report
   
    * IR Resources
       * FAQs
       * Email Alerts
       * Contact IR

 * Contact

Caribou Biosciences, Inc.
2929 7th Street, Suite 105
Berkeley, CA 94710
Tel: 510-982-6030

© 2023 Caribou Biosciences, Inc. All rights reserved.
 * Privacy policy
 * Terms of use

 * Twitter
 * linkedin

Website Design: Hane Chow, Inc.